Swipe om te navigeren naar een ander artikel
We sought to examine how patients’ treatment decisions incorporate potentially conflicting information from standard clinical indicators (e.g., tumor size) and genomic tests for breast cancer recurrence risk. Participants were 77 early stage breast cancer survivors who previously received genomic testing. They read six hypothetical vignettes that varied recurrence risk indicated by standard tests (low or high risk) coupled with the genomic test (low, intermediate or high risk). For each vignette, women reported their perceived recurrence risk and treatment preferences. Test results indicating high recurrence risk increased perception of risk and preference for chemotherapy (p < .001 for all). Perceived risk explained (i.e., mediated) the effect of test results on chemotherapy preferences. When test results conflicted, women gave more weight to genomic over standard test results. Hypothetical genomic test results had the intended effect of influencing women’s perceptions of recurrence risk and interest in chemotherapy.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Albain, K. S., Barlow, W. E., Shak, S., Hortobagyi, G. N., Livingston, R. B., Yeh, I. T., et al. (2010). Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. The lancet Oncology, 11, 55–65. PubMedCrossRef
Dowsett, M., Cuzick, J., Wale, C., Forbes, J., Mallon, E. A., Salter, J., et al. (2010). Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study. Journal of Clinical Oncology, 28, 1829–1834. PubMedCrossRef
Lo, S. S., Mumby, P. B., Norton, J., Rychlik, K., Smerage, J., Kash, J., et al. (2010). Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. Journal of Clinical Oncology, 28, 1671–1676. PubMedCrossRef
Oratz, R., Kim, B., Chao, C., Skrzypczak, S., Ory, C., Bugarini, R., et al. (2011). Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer. Journal of Oncology Practice, 7, 94–99. PubMedCrossRef
Stokes, M. E., Davis, C. S., & Koch, G. G. (2000). Categorical data analysis using the SAS ® system (2nd ed.). Cary: SAS Institute, Inc.
- Understanding how breast cancer patients use risk information from genomic tests
Jessica T. DeFrank
Lisa A. Carey
Noel T. Brewer
- Springer US